104 results on '"Andreasen, P.A."'
Search Results
2. The crystal structure of muPAin-1-IG in complex with muPA-SPD at pH8.5
3. The crystal structure of muPAin-1-IG-2 in complex with muPA-SPD at pH8.5
4. Oestradiol and basic fibroblast growth factor stimulate expression of very low density lipoprotein receptor and plasminogen activator inhibitor-1 in breast carcinoma cell lines
5. The catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
6. The p-aminobenzamidine active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
7. The ligand free catalytic domain of murine urokinase-type plasminogen activator
8. The EGR-cmk active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
9. The catalytic domain of murine urokinase-type plasminogen activator in complex with the active site binding inhibitory nanobody Nb22
10. Crystal structure of uPA in complex with a camelid-derived antibody fragment
11. The crystal structure of upain-1-W3A in complex with uPA at pH7.4
12. The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4
13. Crystal structure of a Hepatocyte growth factor activator inhibitor-1 (HAI-1) fragment covering the PKD-like 'internal' domain and Kunitz domain 1
14. The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4
15. The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4
16. Plasminogen Activators, Tissue Degradation, and Cancer
17. SPECIFIC EFFECTS OF MONOVALENT CATIONS AND OF ADENINE NUCLEOTIDES ON GLUCOCORTICOID RECEPTOR ACTIVATION, AS STUDIED BY AQUEOUS TWO-PHASE PARTITIONING
18. CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines
19. Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis
20. Mutational analysis of plasminogen activator inhibitor-1. Interactions of a-helix F and its neighbouring structural elements regulates the activity and the rate of latency transition
21. Mapping of the epitope for a monoclonal anti-plasminogen activator inhibitor-1 antibody protecting against inactivating agents
22. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor-1: Roles of the reactive centre loop, the shutter region, the flexible joint region, and the small serpin fragment
23. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand
24. The role of β-strand 5A residues of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin
25. Importance of the amino acid composition of the shutter region of plasminogen activator inhibitor-1 for its transition to latent and substrate forms
26. Localization of epitopes for monoclonal anti-urokinase-type plasminogen activator antibodies. Relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme
27. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Implications for antibody-mediated PAI-1 neutralisation and vitronectin binding
28. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism
29. A novel PAI-I inhibitor and its structural mechanism
30. The crystal structure of uPA in complex with the Fab fragment of mAb-112
31. The crystal structure of human urokinase-type plasminogen activator catalytic domain
32. The crystal structure of the Fab fragment of pro-uPA antibody mAb-112
33. Alpha-2 macroglobulin receptor/LDL receptor-related protein (LRP)-dependent internalization of the urokinase receptor
34. The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4
35. Plasminogen activators in bovine milk during mastitis, an inflammatory disease
36. Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition
37. 171 Mechanisms of neutralization of the inhibitory activity of PAI-1 by monoclonal antibodies directed against the β-strand 1A/α-helix F region
38. Dimeric αs2-casein, a novel matrix for tissue-type plasminogen activator catalyzed plasminogen activation
39. 164 Conformational differences between free and complexed forms of uPA and PAI-1, as probed by proteolytic susceptibility
40. 163 Vitronectin induces conformational changes of the hinge of the reactive centre loop and of β-strand 5A and affects inhibitor-to-substrate transition of PAI-1
41. 36 Plasminogen activator inhibitor type-1 inhibits integrin- and vitronectin-dependent cell migration
42. Binding of plasminogen and tissue-type plasminogen activator to dimeric αs2-casein accelerates plasmin generation
43. 648 Prognostic significance of UPA and PAI-1 in relation to other prognosticators for the clinical outcome of breast cancer
44. Plasminogen activators in bovine milk during mastitis, an inflammatory disease
45. Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats
46. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
47. Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator
48. Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma
49. Inactive proenzyme to tissue‐type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
50. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one‐step affinity purification.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.